Posterior Reversible Encephalopathy Syndrome in ALL
1Division of Neurology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL; Departments of Pediatrics and Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL.
Pediatric acute lymphoblastic leukemia (ALL) patients may develop posterior reversible encephalopathy syndrome (PRES) after chemotherapy. This study investigated the mechanisms and treatment of PRES in these young patients.
Area of Science:
- Neurology
- Pediatric Oncology
- Hematology
Background:
- Posterior reversible encephalopathy syndrome (PRES) is a neurological disorder.
- Acute lymphoblastic leukemia (ALL) is a common childhood cancer.
- Chemotherapy for ALL can have serious side effects.
Purpose of the Study:
- To investigate the pathogenesis of PRES in pediatric ALL patients.
- To explore treatment strategies for PRES in this population.
- To understand the clinical characteristics of PRES in pediatric ALL.
Main Methods:
- Retrospective analysis of 11 pediatric ALL cases.
- Review of clinical data, neuroimaging, and treatment outcomes.
- Analysis of potential pathogenetic mechanisms.
Main Results:
- PRES occurred in 11 pediatric ALL patients post-induction chemotherapy.
- Identified potential risk factors and clinical manifestations.
- Evaluated the efficacy of different treatment approaches.
Conclusions:
- PRES is a significant complication in pediatric ALL patients undergoing chemotherapy.
- Understanding pathogenetic mechanisms can guide treatment.
- Further research is needed to optimize PRES management in pediatric ALL.
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
08:31Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025